135 results about "Endotoxemias" patented technology

A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

The invention provides micelles, pharmaceutical formulations comprising micells, solutions comprising micells, methods for preparing micells, methods for delivering micells to patients, and methods for treating sepsis, endotoxemia, septic shock and systemic inflamatory response syndrome in patients by adiministering micelles. The micelles comprises compounds of Forumala (A): wherein the substituents are as defined herein.

The present invention relates to a ring amino acid adsorbing agent and its preparation method. It uses natural macromolecule as carrier, its grain size is 0.45-0.9 mm, it is formed from resin which has amino acid ligand with fixed effective dose after activation of epoxy chloropropane, in which amino acid content is 12.5-39.7 micro mol / ml resin, and the described ligand is: amino acid, polyamino acid, polypeptide or protein. It can be directly used for blood perfusion method to cure the diseases of rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, endotoxemia and infective shock, etc. The animal tests show that adsorbing agent has no toxic side effect and heat source. It is a good medical blood-cleaning adsorption material.

The invention relates to an endotoxin adsorbent, which in detail relates to a method of preparing endotoxin adsorbent for blood perfusion. The method employs spherical agarose gel with good biocompatibility as base material, employs epichlorohydrin, hexamethylene diamine, 1, 1'-carbonyldiimidazole as activating agent, and bonds polymyxin B for endotoxin removal. The invention is characterized in that it overcomes the toxicity of cyanogen bromide and instability of aglycone, improves the safty and reliability of operation, reducesnon-specific adsorption through bonding polymyxin B with 1, 1'-carbonyldiimidazole, and improves biocompatibility of adsorbent and suits for treating endotoxemia. The invention is also characterized by simple experimental procedure and high clearance for endotoxin.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the novel medical usage of icaritin, in particular to the usage of icaritin in preparation of medicine for preventing and treating endotoxemia. Lipopolysaccharide (LPS) is used for stimulating the macrophage system RAW264.7 of a mouse and establishing an extraneous endotoxic inflammation model, LPS is used for stimulating the C57BL / 6J mouse and establishing the endotoxemia animal model, icaritin is adopted for intervention, and dexamethasone is used as reference. The experiment result shows that the icaritin can reduce the death rate, the level of the inflammatory factor, the inflammatory mediator and the adhesion molecules and infiltration of inflammatory cells of the tissue after the mouse is attacked by endotoxin, and proves that the icaritin can effectively prevent and treat endotoxemia and can be used for further preparing effective drug for preventing and treating endotoxemia, including dosage forms such as oral and enteric capsules or intravenous injections.

The invention relates to endotoxin adsorbing material for curing endotoxemia in the bioseparation and the biomedical engineering fields. The adsorbing material which takes sepharose gel as a carrier is coupled with spacer arm molecules through the activating reaction, and then is coupled with two groups of quarternary ammonium salt cations and dewatering molecules as functional groups to be prepared. The adsorbing material is simultaneously coupled with the two groups of functional groups mutually effected with endotoxin, and further the adsorbing selectivity of the adsorbing material to the endotoxin is improved. The physicochemical property of the adsorbing material is steady, and the adsorbing material has good blood compatibility, thereby being able to used for removing the endotoxin in blood plasma, and curing the endotoxemia. The preparation process of the adsorbing material is simple, the preparation cost is low, and the adsorbing material belongs to the novel endotoxin adsorbing material.

Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.

An endotoxic adsorpting method for treating endotoxemia and anaphylactic reaction caused by endotoxemia is prepared through activating the hydroxy group of agarose gel or DVA as carrier by cyanogen bromide or epoxy chloropropane or sulfuryl chloride, and adding polymyxin solution.

The invention discloses an oil emulsion containing banksia rose oil and its preparing process, wherein the emulsion comprises rich costunolide and dehydrogenated costuslactone. The invention also provides its use in preparing medicament for the treatment of endotoxemia caused by various reasons.

The invention discloses an endotoxin adsorption material for blood purification and a preparation method and application of the endotoxin adsorption material for blood purification.The endotoxin adsorption material for blood purification is obtained by coupling reaction of an active carrier and genins containing aminos, wherein the ratio of the active carrier to every genin is 10:1-100:1; the active carrier is obtained by reaction between a carrier and a bis-glycidyl ether coupling reagent, wherein the carrier is a spherical natural polymer with the particle size being 0.05-1.5mm, and the volume ratio of the carrier to the bis-glycidyl ether coupling reagent is 1:0.5-1:10.The endotoxin adsorption material for blood purification has the advantages of high specificity, good blood compatibility, high endotoxin adsorption efficiency and capability of being used for blood purification and adsorption treatment of endoxemia clinically.The preparation method is simple, convenient, simple and short in process route and safe for preparation.

The invention discloses a perfusion medicament for treating milk cow mastitis and a preparation method thereof. The perfusion medicament is prepared from the following raw materials by weight: 0.9-4.3g of cefquinome sulphate, 0.15-0.25g of prednisolone, 0.5-1.3g of flunixin meglumine, 1-1.5g of glycerin monostearate, 3-8g of Vaseline, 0.05g of ethylparaben and 65-70g of whiteruss. The preparationmethod comprises the following specific steps of: (1) putting one tenth of the liquid paraffin into a burdening tank in a certain weight ratio; (2) adding one third of the liquid paraffin into a heating tank; and (3) putting the rest of the liquid paraffin left after the steps (1) and (2) and auxiliary materials in the step (2) into an emulsifying tank, adding 0.9-4.3g of cefquinome sulfate in a certain weight ratio, and stirring till uniform distribution to obtain the perfusion medicament for treating milk cow mastitis. The perfusion medicament has the advantages of no induction of endotoxemia in a milk cow mastitis treating process, remarkable curative effect on mastitis and freeness from medicament tolerance.

The present invention relates to a use of a pharmaceutical composition in the manufacture of medicament for treating related diseases caused by endotoxemia. The pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or pharmaceutically acceptable salt thereof and borneol. The diseases include, but are not limited to, systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, sepsis related disseminated intravascular coagulation, acute lung injury, acute respiratory distress syndrome, multiple organ failure syndrome, septic brain injury and inflammatory lung injury caused by other reasons, including but not limited to bacterial pneumonia.

The invention relates to a synthetic composition comprising one or more human milk monosaccharides and / or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and / or low-grade inflammation in patients with metabolic disorders.

The invention belongs to a culture technique of Chinese medical plants, relating to a method for artificially culturing Chinese medicinal plant of Chinese pulsatilla root. The Chinese pulsatilla root is commonly used traditional Chinese medicine, and has the functions of antibiosis, pathogen resistance, dampness elimination, insect control, body immunity enhancement, cancer resistance, anti-inflammatory, poison resistance, heat and toxic material clearing, blood cooling and diarrhea stopping, calmness, pain relieving, endotoxemia resistance and the like. Currently, Chinese medicinal plants of Chinese pulsatilla root all around the world grow widely; the artificially cultured Chinese medicinal plant of Chinese pulsatilla root in the invention comprises the techniques such as seed cold storage, gibberellin seed soaking, wet sand pregermination, seeding and field management, and Chinese medical plant harvest. The invention has the advantages that the artificial culturing technique of Chinese pulsatilla root is integral; the culturing measurement is simple, practical and reliable, the rate of germination is improved, and the saponin content of Chinese pulsatilla root is ensured, thereby improving medicinal material therapy.

The present invention relates to a compound medicine granule preparation for effectively curing entero toxemia and its preparation method. Its composition includes the following main components: rhubarb 0.1-10kg, bitter orange 0.1-8kg, magnolia bark 0.1-8kg and mirabilite 0.01-3kg. Said invention also provides the concrete steps of its preparation method.

The present invention relates to the use of endotoxin neutralizing protein (ENP) and derivatives thereof as stand alone microbial inhibitors or as synergistic enhancers of antibiotics and preservatives. Compositions comprising ENP or alone or in combination with an antibiotic may be used to prevent or treat gram-negative bacterial infections, endotoxemia, septic shock, gram-positive bacterial infections, yeast infections and fungal infections. Compositions comprising ENP alone or in combination with a conventional preservative may be used as antimicrobial preservative in cosmetic or personal care preparations.

The invention discloses a drug for treating severe acute pancreatitis. The drug is made from bupleurum, corydalis tuber, oriental wormwood, fermented soybean, immature orange fruit, white atractylodes rhizome, oriental water plantain and Chinese aloe according to a certain weight proportion. The drug has protective effect on the intestinal barrier function under the condition of the severe acute pancreatitis, can lower intestinal tract permeability, lighten endotoxemia and inflammatory reaction, and has greater influence on outcome of diseases.

The invention discloses a dahurian angelica root drug mellow distilling liquid effective constituent group finger print and buildup method and the application. The method includes the distilling of dahurian angelica root drug and the buildup of mellow distilling liquid effective constituent group finger print and gaining the dahurian angelica root drug mellow distilling liquid effective constituent group finger print. It separates finger print to three area, II area and III area is the main effective constituent group. The II area is mainly relative to fever allaying, anti-inflammation, antiendotoxin, and the III area is mainly relative to ease pain and excitement allaying function. The finger print has high repeatability and good stability. It could be used to test the chemical constituent in dahurian angelica root, and also could be used as the identification and quantity control method, and could develop new drugs from the effective constituents in distilling liquid.

Compositions comprising Hirsutella sinensis mycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extracting Hirsutella sinensis mycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.

The present invention relates to one kind of Chinese medicine composition for treating endotoxemia and its preparation process. The Chinese medicine composition consists of effective components prepared with capillary artemisia, cape jasmine, rhubarb, red sage, honeysuckle and other five kinds of Chinese medicinal materials in certain weight proportion, and pharmaceutically acceptable carrier. The Chinese medicine composition is used in treating endotoxemia and various diseases with endotoxemia complication, and has especially high curative effect on endotoxin induced endotoxin shock and multiple organ incompetence.

The present invention relates to methods for treating systemic inflammation. In certain embodiments, the method comprises administering a therapeutically effective amount of curcumin-selenium loaded nanoparticles. The curcumin-selenium loaded nanoparticles can comprise a matrix of chitosan, polyethylene glycol and tetramethoxysilane encapsulating curcumin and selenium. In certain embodiments, the method comprises administering a therapeutically effective amount of nitric oxide-releasing nanoparticles. The nitric oxide-releasing nanoparticles can comprise a matrix of chitosan encapsulating nitric oxide. In certain embodiments, the systemic inflammation can be caused by endotoxemia. In certain embodiments, the systemic inflammation can be caused by a Filovirus, including an Ebola virus or a Marburg virus. In certain embodiments, the methods for treating systemic inflammation in a subject result in the reduction of proinflammatory cytokines in a subject. In certain embodiments, the method of treatment is a combination therapy. The present invention also relates to methods of making compositions comprising nanoparticles.

The invention provides an arenicola cristata antibacterial peptide NZ17074 derived peptide N6 and application thereof. An antibacterial peptide NZ17074 molecular structure is optimally designed to obtain a novel derived peptide N6, and the amino acid sequence of the novel derived peptide N6 is shown as SEQ ID NO: 1. The antibacterial peptide N6 provided by the invention has a very good sterilization effect on Gram-negative bacteria, and is used for remarkably reducing the haemolytic activity on mouse erythrocytes and the cytotoxicity on mouse original macrophages. A mouse toxemia model test result shows that the antibacterial peptide N6 also has an endoxemia resisting effect, and can be used for remarkably improving the survival rate of mice, and the effect of the antibacterial peptide N6 is better than that of an antibiotic polymyxin. The antibacterial peptide N6 has small molecular weight and is easily artificially synthesized; the antibacterial peptide N6 is a low-molecular-weight polypeptide with extremely good application value, can be used for preparing novel antibacterial and anti-infection medicines and the like, and has a good application prospect.

The present invention provides an agent for preventing and / or treating cachesia comprising TCF-II as an effective ingredient. An excellent agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the present invention and useful for medicine.

The invention relates to pharmaceutical applications of poly-cationic resin and is based on treatment on metabolic diseases due to intestinal flora disorder by orally taking the poly-cationic resin, wherein the metabolic diseases include but not limit to: 1) non-alcoholic fatty liver, nonalcoholic steatohepatitis, hepatic fibrosis caused by intestinal bacterial toxin; 2) diabetes type II; 3) central obesity metabolic syndromes; 4) endotoxemia; etc.

The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

The invention discloses an analog peptide molecule of antiendotoxin factor of Limulida to kill bacteria and treat endotoxin blood symptom, which applies computer molecular analog technique to design the following 6 groups of analog peptides antiendotoxin factor of Limulida based on GOR method with TALF functional area position as mould: RX1 NPT X2 KRLK X3 KYKGK X3 WCP as the first group, X4 INPT X2 KR X1 X4 X3 KYKGKFW as the second group, INPT X2 KRLKW X4 YKGR X3 X3 CP as the third group, PT X2 KR X1 KX3 KYKGKFWCP as the forth group, K X2 NPTVKR X1 K X3 RYKGKF as the fifth group, NPX5 VKR X1 K X3 RYKGKF as the sixth group, wherein six groups are synthesized into the peptide through solid phased peptide synthetic method by self-synthesizing and manual synthesizing, which produces the peptide with sterilizing and / or neutralizing LPS activity.

A medicine for decreasing the content of endotoxin in human blood and treating endotoxemia, obstructive jaundice, pancreative and various shocks is prepared from rhein and danshensu.

Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.